Академический Документы
Профессиональный Документы
Культура Документы
PG-2, Sem-4
Inorganic chemistry
2017
Contents
Introduction
Structural features
Biological function of CA
application
Carbonic anhydrase is a Zn(II) containing metalloenzyme
This enzyme was first identified in 1933, in red blood cells of cows
This enzyme has been found in virtually all living system, however only
members of alpha-CA gene family are found in mammals
It is located in red blood cells, pancreatic cells, gastric mucosa, renal tubules
Structural features
In all isoenzymes , there exists one Zn(II) site per molecule.
There are at least five distinct CA families ( alpha, beta, gamma, delta and
zeta). These families have no significant amino acid sequence similarity .The
alpha CA s are found in humans
(k =10^-1 s-1)
( ( k= 10^6 s-1)
From the rate constant , it is evident that the rate acceleration
by CA at physiological pH is tremendously high . This CA
catalysed equilibration reaction plays an important role as a
buffer in human blood
In red blood cells, this enzyme performs the important role of receiving CO2 from
tissues such as active muscles and releasing in the alveoli of the lungs
CA also helps to control fluid balance in different parts of the body i.e. eye ,
kidney. This enzyme also function in the formation of Hydrochloric acid by the stomach
1. Prosthetic group
Crucial step
Plausible catalytic cycle of CA
Step 1 : deprotonation
Step 2: Carboxylation
The anionic oxygen then performs a nucleophillic
attack on carbon
Step 3 : Formation of Ring Structure
Addition of water
displaces the
bicarbonate ion
4. Inhibition of enzymatic activity - The enzymatic activity is
very often inhibited by different anions like I- ,SH- ,N3 - ,CN- ,CNO- etc. and
neutral substances like sulfonamides (RCO2NH2) and imidazole. Probably
these inhibitors are positioned in a pocket close to the Zn(II) site . This
attachment blocks the active site of CA
Medical Application
Treat Glaucoma
Carbonic anhydrase inhibitors, Sulfonamides are used in the treatment of
glaucoma to reduce the intraocular pressure (IOL) that has build up inside the
eye by 40% to 60% through blocking the enzyme action.